Intellia Therapeutics Priced, Nasdaq: NTLA

Preclinical biotech developing gene editing therapies using CRISPR/Cas9 technology.

Industry: Health Care

Latest Trade: $23.93 0.00 (0.0%)

First Day Return: +22.8%

Return from IPO: +32.9%

Industry: Health Care

We are a leading gene editing company focused on the development of proprietary, potentially curative therapeutics utilizing a recently developed biological tool known as the CRISPR/Cas9 system. We believe that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. We intend to leverage our leading scientific expertise, clinical development experience and intellectual property position to unlock broad therapeutic applications of CRISPR/Cas9 gene editing and develop a potential new class of therapeutic products.
more less
IPO News for Intellia Therapeutics
more
IPO Data
IPO File Date 04/11/2016
Offer Price $18.00
Price Range $16.00 - $18.00
Offer Shares (mm) 6.0
Deal Size ($mm) $108
IPO Data
IPO Date 05/05/2016
Offer Price $18.00
Price Range $16.00 - $18.00
Offer Shares (mm) 6.0
Deal Size ($mm) $108
Underwriters
more
Company Data
Headquarters Cambridge, MA
Founded 2014
Employees 61
Website www.intelliatx.com